Rimonabant, a selective CB1R antagonist, inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor–deficient mice, partially by reducing IL-1β–mediated pro-inflammatory gene expression (204). Here, IL1B is linked to atherosclerosis.